Market Insight : Diabetes Market Globally Grow at a CAGR of 8.05% by Revenue During the Forecast Period 2017-2020
Researchmoz added Most up-to-date research on "Global Type 1 Diabetes Market 2016-2020" to its huge collection of research reports.
Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered :
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
Segments based on geography:
Americas
APAC
EMEA
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Eli Lilly and Company
Novo Nordisk A/S
Sanofi SA
Other prominent vendors
Adocia
Astellas Pharma
AstraZeneca
Baxalta
BHV Pharma
Biocon
Biodel
Boehringer Ingelheim
CureDM
Dance Biopharm
Diamyd Therapeutics AB
Diasome Pharmaceuticals
DiaVac
Exsulin
Gan & Lee Pharmaceuticals
Generex Biotechnology
Key driver
Increase in prevalence of type 1 diabetes
For a full, detailed list, view our report
Key challenge
Poor storage conditions and distribution policies for insulin
For a full, detailed list, view our report
Key trend
Awareness programs and initiatives
For a full, detailed list, view our report
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://researchreportlife.blogspot.in//
Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered :
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
Segments based on geography:
Americas
APAC
EMEA
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Eli Lilly and Company
Novo Nordisk A/S
Sanofi SA
Other prominent vendors
Adocia
Astellas Pharma
AstraZeneca
Baxalta
BHV Pharma
Biocon
Biodel
Boehringer Ingelheim
CureDM
Dance Biopharm
Diamyd Therapeutics AB
Diasome Pharmaceuticals
DiaVac
Exsulin
Gan & Lee Pharmaceuticals
Generex Biotechnology
Key driver
Increase in prevalence of type 1 diabetes
For a full, detailed list, view our report
Key challenge
Poor storage conditions and distribution policies for insulin
For a full, detailed list, view our report
Key trend
Awareness programs and initiatives
For a full, detailed list, view our report
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://researchreportlife.blogspot.in//
Comments
Post a Comment